A Trial to study the effects of two drugs travoprost & brimonidine/timolol combination in patients with kanchbind (high pressure in eyes).

A comparative study on safety & efficacy of travoprost & brimonidine/timolol fixed combination in patients of primary open angle Glaucoma at ophthalmology department of Peoples College of Medical Sciences & Research Centre Bhanpur Bhopal.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/11/002105

Enrollment

Registered

2011-11-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- glaucoma

Interventions

Intervention1: brimonidine/timolol: brimonidine/timolol eye drops twice daily for 12weeks Control Intervention1: travoprost: travoprost eye drops once daily for 12 weeks

Eligibility

Inclusion criteria

Inclusion criteria: IOP in each eye more than 21 mm Hg. Best corrected visual acuity 6/18 or better in each eye.

Exclusion criteria

Exclusion criteria: Progressive or functionally significant visual fields loss within past year. Pregnant women or lactating mothers. Patients with corneal abnormalities or any other conditions that prevent applanation tonometry. Patients with ocular infection, advanced cataract, ocular inflammation. Patients of bronchial asthma & cardiac disease. Â

Design outcomes

Primary

Measure	Time frame
Visual acuity IOP Slit lamp Bimicroscopy for optic disc evaluation Gonioscopy PerimetryTimepoint: 4, 8, 12 wks	—

Secondary

Measure	Time frame
Visual acuity IOP Slit lamp Bimicroscopy for optic disc evaluation Gonioscopy Perimetry Timepoint: 4, 8, 12 wks	—

Countries

India

Contacts

Public Contactrekha mehani

Peoples college of medical sciences and research center bhanpur Bhopal

shukladrsd9@gmail.com9893733897

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026